Evaluation of an orthogonal pooling strategy for rapid high-throughput screening of proteases.

Orthogonal pooling was evaluated as a strategy for the rapid screening of multiple cysteine and serine proteases against large compound libraries. To validate the method the human cysteine protease cathepsin B was screened against a library of 64,000 individual compounds and also against the same library mixed 10 compounds per well. The orthogonal pooling method used resulted in each compound being present in two wells, mixed with a different set of nine other compounds in each location. Thus hits were identified based on activity in both locations, avoiding the need for retesting of each component of active mixtures. Hits were tested in dose-response both in the dithiothreitol (DTT)-containing buffer used in the primary HTS and in buffer containing cysteine in place of DTT to rule out artifacts due to oxidative inactivation of the enzyme. Comparison of the confirmed actives from single-compound and mixture screening showed that mixture screening identified all of the actives from single-compound HTS. Based on these results the orthogonal pooling strategy has been used successfully to rapidly screen several cysteine and serine proteases.

[1]  A. Barrett,et al.  L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. , 1982, The Biochemical journal.

[2]  F. Jänicke,et al.  [Clinical and prognostic significance of tumor-associated proteases in gynecologic oncology]. , 1991, Geburtshilfe und Frauenheilkunde.

[3]  S. Whelan,et al.  Endosomal Proteolysis of the Ebola Virus Glycoprotein Is Necessary for Infection , 2005, Science.

[4]  A. Maseri,et al.  Age Dependence of Ischaemic Heart Syndromes and the Contribution of Haemostatic Deviations , 1992 .

[5]  O. Vasiljeva,et al.  Emerging roles of cysteine cathepsins in disease and their potential as drug targets. , 2007, Current pharmaceutical design.

[6]  S. Michaud,et al.  Cathepsin B inhibitors as potential anti-metastatic agents , 1998 .

[7]  John Q Trojanowski,et al.  High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. , 2007, Biochemical and biophysical research communications.

[8]  Bonnie F. Sloane,et al.  Cysteine cathepsins in human cancer , 2004, Biological chemistry.

[9]  Bohn Stafleu van Loghum,et al.  Online … , 2002, LOG IN.

[10]  Caroline Engeloch,et al.  Statistical evaluation of a self-deconvoluting matrix strategy for high-throughput screening of the CXCR3 receptor. , 2005, Assay and drug development technologies.

[11]  S. Gobec,et al.  Inhibitors of cathepsin B. , 2006, Current medicinal chemistry.

[12]  B. Haagmans,et al.  Coronaviruses and their therapy , 2006, Antiviral Research.

[13]  Richard Spann,et al.  High capacity screening of pooled compounds: Identification of the active compound without re‐assay of pool members , 1996 .

[14]  Kathryn L. Schornberg,et al.  Role of Endosomal Cathepsins in Entry Mediated by the Ebola Virus Glycoprotein , 2006, Journal of Virology.

[15]  V. Turk,et al.  Apoptotic Pathways: Involvement of Lysosomal Proteases , 2002, Biological chemistry.

[16]  Michael C. Myers,et al.  Identification and characterization of 3-substituted pyrazolyl esters as alternate substrates for cathepsin B: the confounding effects of DTT and cysteine in biological assays. , 2007, Bioorganic & medicinal chemistry letters.

[17]  Brian Hudson,et al.  Strategic Pooling of Compounds for High-Throughput Screening , 1999, J. Chem. Inf. Comput. Sci..

[18]  V. Turk,et al.  Lysosomal Cysteine Proteases: Structural Features and their Role in Apoptosis , 2005, IUBMB life.